Bulletin of Experimental Treatments for AIDS, No. 26 September 1995
Ronald Baker, PhD

One outspoken critic of the Columbia findings is Robert Gallo, MD, of the National Cancer Institute (NCI). Some other scientists have become skeptical as well, inclding Parkash Gill, MD, of the University of Southern California and Robert Biggar, MD, at NCI. Still other researchers, such as Steven Miles, MD, of the University of California in Los Angeles (UCLA), remain convinced that KSHV is the cause of KS. Robert Yarchoan, MD, of the NCI and other investigators are planning studies of the anti-herpes drug foscarnet to treat KS, based on the assumption that KSHV plays a key role in the development of the malignancy among people with AIDS. See pages 58-59 of June 1995 BETA for more information on foscarnet treatment of KS.

950901
BETA2623

Copyright © 1995 - Bulletin of Experimental Treatments for AIDS (BETA). Reproduced with permission. BETA is published four times a year by the San Francisco AIDS Foundation. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. Call 415.487.8060; FAX: 415.487.8069. Mailing Address: P.O. Box 426182, San Francisco, CA 94142-6182.  beta@sfaf.org  http://www.sfaf.org/beta.html